| | Business Summary | | Crucell
N.V.
was
formed
as
the
result
of
the
merger
of
IntroGene
BV
and
U-BiSys
BV.
Crucell
will
integrate
IntroGene'
s
existing
human
cell
line
expression
platform,
PER.C6,
and
U-BiSys'
phage
antibody-display
library
technology,
which
enables
the
creation
of
fully
human
monoclonal
antibodies,
thus
forming
a
powerful
platform
for
the
discovery
of
drug
targets,
and
the
development
and
production
of
human
biopharmaceuticals.
PER.C6
has
been
widely
adopted
by
the
pharmaceutical
industry,
with
licensing
agreements
signed
with
Merck
&
Co.
Inc.,
Glaxo
Wellcome/SmithKline
Beecham,
Novartis
(through
its
wholly
owned
subsidiary,
Systemix),
Aventis
Pharmaceuticals
Products
Inc.,
Schering
AG
(Berlex
Biosciences),
Genzyme
Corporation,
Pfizer/Warner
Lambert,
Transgene
SA,
Oxford
BioMedica
(UK)
Ltd.,
BioHeart
Inc.,
and
ML
Therapeutics
Ltd./Cobra.
U-BiSys'
phage
antibody-display
and
antibody
engineering
technologies
will
complement
IntroGene's
applications
of
PER.C6. | | More
from
Market Guide: Expanded
Business Description |
| | Financial Summary | | CRXL
is
a
biotechnology
company
that
combines
two
innovative
technological
platforms
to
provide
a
powerful
and
effective
means
to
discover,
develop
and
produce
a
variety
of
biopharmaceuticals
for
the
treatment
of
human
diseases.
For
the
six
months
ended
6/01,
revenues
rose
41%
to
EUR2.2
million.
Net
loss
fell
86%
to
EUR12.7
million.
Results
reflect
an
increase
in
license
revenues
and
government
grants
and
the
absence
of
a
$84.1
million
acquired
R&D
charge. | | More
from
Market Guide: Significant
Developments |
| | Officers | |
| Position | | Pieter Strijkert | Chairman | | Domenico Valerio | Pres,
CEO | | Ronald Brus | Exec.
VP | | Leonard Kruimer | VP,
CFO | | Arsia Amir-Aslani, Ph.D. | VP,
Corp. Devel. and Strategy |
| More
from
Market Guide on Officers & Directors:
Expanded
List, Bios,
Compensation,
Options
|
|
![[one-year price graph]](http://chart.yahoo.com/c/0b/c/crxl.gif)